GREY:IMVIF - Post Discussion
Post by
Breakthorough1 on Aug 13, 2023 2:44am
October 8th 2020
"
In consultation with Health Canada, IMV decided to combine its original Phase 1 and 2 studies into a single trial with the potential to accelerate the clinical development and the timeline of the overall project. In collaboration with its lead investigators for the Phase 1/2 clinical study, Joanne Langley, MD, and Scott Halperin, MD, of the Canadian Center for Vaccinology, the design of this larger study will incorporate the same two-age strata cohorts (18-55 years old and over 55 years old) as originally designed. The Phase 1/2 trial is expected to be initiated before the end of 2020 after the completion of the preclinical safety, GLP toxicology and challenge studies that are required to advance into Phase 1/2 studies. These preclinical studies have been ongoing since mid-August."
https://www.imv-inc.com/investors/press-releases/detail/661/imv-provides-updates-on-covid-19-vaccine-program
Be the first to comment on this post